Literatura ACTA MEDICINAE 5–6/2018 Onkogynekologie | Gynekologie

Léčba karcinomu ovaria

doc. MUDr. Michal Zikán, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a Nemocnice Na Bulovce

1 **Dušek, L. – Mužík, J. – Kubásek, M. – Koptíková, J. – Žaloudík, J. – Vyzula, R.**: Epidemiologie zhoubných nádorů v České republice. Masarykova univerzita, 2005, dostupné z: http://www.svod.cz, verze 7.0, 2007, vyhledáno 4. 4. 2018.

2 **Pinsky, P. F. – Yu, K. – Kramer, B. S., et al.**: Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. *Gynecol Oncol*, 2016, 143, s. 270–275.

3 **Jacobs, I. J. – Menon, U. – Ryan, A., et al.**: Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. *Lancet*, 2016, 387, s. 945–956.

4 **Rosenthal, A. N.**: Ovarian cancer screening in the high-risk population – the UK Familial Ovarian Cancer Screening Study (UKFOCSS). *Int J Gynecol Cancer*, 2012, 22, suppl. 1, s. S27–S28.

5 **Widschwendter, M. – Apostolidou, S. – Jones, A. A., et al.**: HOXA-methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study. *Int J Cancer*, 2009, 125, s. 2214–2218.

6 **Pisano, C. – Bruni, G. S. – Facchini, G., et al.**: Treatment of recurrent epithelial ovarian cancer. *Ther Clin Risk Manag*, 2009, 5, s. 421–426.

7 SPC Avastin, dostupné z: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf, vyhledáno 6. 4. 2018.

8 **Burger, R. A. – Brady, M. F. – Bookman, M. A., et al.**: Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med*, 2011, 365, s. 2473–2483.

9 **Oza, A. M. – Cook, A. D. – Pfisterer, J., et al.**; ICON7 trial investigators: Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. *Lancet Oncol*, 2015, 16, s. 928–936.

10 **Aghajanian, C. – Goff, B. – Nycum, L. R., et al.**: Final overal survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. *Gynecol Oncol*, 2015, 139, s. 10–16.

11 **Poveda, A. M. – Selle, F. – Hilpert, F., et al.**: Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III AURELIA trial. *J Clin Oncol*, 2015, 33, s. 3836–3838.

12 **Pfisterer, J. – Plante, M. – Vergote, I., et al.**: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: Winter group trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. *J Clin Oncol*, 2006, 24, s. 4699–4707.

13 **Luvero, D. – Milani, A. – Ledermann, J. A.**: Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. *Ther Adv Med Oncol*, 2014, 6, s. 229–239.

14 **Rouleau, M. – Patel, A. – Hendzel, M. J., et al.**: PARP inhibition: PARP1 and beyond. *Nat Rev Cancer*, 2010, 10, s. 293–301.

15 **Venkitaraman, A. R.**: Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. *Science*, 2014, 343, s. 1470–1475.

16 **Chen, S. – Parmigiani, G.**: Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol*, 2007, 25, s. 1329–1333.

17 **Tan, D. S. – Rothermundt, C. – Thomas, K., et al.**: „BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. *J Clin Oncol*, 2008, 26, s. 5530–5536.

18 **Ledermann, J. – Harter, P. – Gourley, C., et al.**: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. *Lancet Oncol*, 2014, 15, s. 852–861.

19 **Ledermann, J. – Harter, P. – Gourley, C., et al.**: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med*, 2012, 366, s. 1382–1392.

Screening karcinomu děložního hrdla – cytologie, nebo typizace HPV?

MUDr. Jan Chytra | doc. MUDr. Jiří Bouda, Ph.D. Gynekologicko-porodnická klinika, LF UK a FN Plzeň

1 ECDC Guidance. Introduction of HPV vaccines in European Union Countries – an update. Stockholm, ECDC, 2012.

2 **Leyden, W. A. – Manos, M. M. – Geiger, A. M., et al.**: Cervical cancer in women with comprehensive health care access: attributable factors in the screening proces. *J Natl Cancer Inst*, 2005, 97, s. 675–683.

3 **Whitlock, E. P. – Vesco, K. K. – Eder, M., et al.**: Liquid-based cytology and human papillomavirus testing to screenfor cervical cancer: A systematic review for the U.S. preventive services task force. *Ann Intern Med*, 2011, 155, s. 687–697.

4 **Dušek, L. – Mužík, J. – Kubásek, M., et al.**: Epidemiologie zhoubných nádorů v České republice. Masarykova univerzita, 2005. Dostupné z: http://www.svod.cz, verze 7.0 [2007], vyhledáno 15. 4. 2018.

5 MZ ČR, vyhláška č. 70/2012 Sb., o preventivních prohlídkách. Dostupné z: http://www.mzcr.cz/Soubor.ashx?souborID=18384&typ=application/pdf&nazev=Vyhl%C3%A1%C5%A1ka+o+preventivn%C3%ADch+prohl%C3%ADdk%C3%A1ch+%C4%8D.+70+z+roku+2012.pdf, vyhledáno 15. 4. 2018.
Věstník MZ ČR 7/2007. Dostupné z: https://www.mzcr.cz/Legislativa/dokumenty/vestnik_3621_1772_11.html, vyhledáno 15. 4. 2018.

6 **Katki, H. A. – Kinney, W. K. – Fetterman, B., et al.**: Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: A population-based study in routine clinical practice. *Lancet Oncology*, 2011, 12, s. 663–672.

7 *Fakta o LBC v otázkách a odpovědích* (LBC – liquid based cytology). Gynekologové spolupracující s Bioptickou laboratoří, s. r. o., poskytují ThinPrep PAP test. Dostupné z: http://www.gynekolog.cz/thinprep-pap/fakta, vyhledáno 15. 4. 2018.

8 **Wright, T. C. – Stoler, M. H. – Behrens, C. M., et al.**: Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test. *Gynecologic Oncology*, 2015, 136, s. 189–197.

9 **Wentzensen, N. – Schiffman, M. – Palmer, T., et al.**: Triage of HPV positive women in cervical cancer screening. *J Clin Virology*, 2016, 76, s. S49–S55.

10 **Fairley, C. K. – Hocking, J. S. – Gurrin, L. C., et al.**: Rapid decline in presentations of genital wals after the implementation of a national quadrivalent human papilloma virus vaccination programme for young women. *Sexually Transmitted Infections,* 2009, 85, s. 499–502.

Zachování fertility u žen léčených pro zhoubný nádor

MUDr. Kristýna Frühaufová, Ph.D. Iscare IVF, Praha

1 **Salama, M. – Winkler, K. – Murach, K. F., et al.**: Female fertility loss and preservation: threats and opportunities. *Ann Oncol*, 2013, 24, s. 598–608.

2 **McLaren, J. F. – Bates, G. W.**: Fertility preservation in women of reproductive age with cancer. *Am J Obstet Gynecol*, 2012, 207, s. 455–462.

3 **Martinez, F.**: Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspective. *Fertil Steril*, 2017, 108, s. 407–415.

4 **Roberts, J. – Ronn, R. – Tallon, N. – Holzer, H.**: Fertility preservation in reproductive-age women facing gonadotoxic treatments. *Curr Oncol*, 2015, 22, s. 294–304.

5 **Wallace, W. H. – Thomson, A. B. – Saran, F. – Kelsey, T. W.**: Predicting age of ovarian failure after radiation to a field that includes the ovaries. *Int J Radiat Oncol Biol Phys*, 2005, 62, s. 738–744.

6 **Chung, K. – Donnez, J. – Ginsburg, E. – Meirow, D.**: Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients. *Fertil Steril*, 2013, 99, s. 1534–1542.

7 **Gubbala, K. – Gallos, I. – Pathiraja, P., et al.**: Outcomes of ovarian transposition in gynaecological cancers; a systematic review and meta-analysis. *J Ovarian Res*, 2014, 7, s. 69.

8 **Lambertini, M. – Ceppi, M. – Poggio, F., et al.**: Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. *Ann Oncol*, 2015, 26, s. 2408–2419.

9 **Lambertini, M. – Goldrat, O. – Toss, A., et al.**: Fertility and pregnancy issues in BRCA-mutated breast cancer patients. *Cancer Treat Rev*, 2017, 59, s. 61–70.

10 **Tomasi-Cont, N. – Lambertini, M. – Hulsbosch, S., et al.**: Strategies for fertility preservation in young early breast cancer patients. *The Breast*, 2014, 23, s. 503–510.

11 **Cobo, A. – Diaz, C.**: Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. *Fertil Steril*, 2011, 96, s. 277–285.

12 **Cakmak, H. – Rosen, M. P.**: Random-start ovarian stimulation in patients with cancer. *Curr Opin Obstet Gynecol*, 2015, 27, s. 215–221.

13 **Domingo, J. – Guillén, V. – Ayllon, Y., et al.**: Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. *Fertil Steril*, 2012, 97, s. 930–934.

14 **Oktay, K. – Kim, J. Y. – Barad, D. – Babayev, S. N.**: Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. *J Clin Oncol*, 2010, 28, s. 240–244.

15 **Dahan, M. H. – Tan, S. L. – Chung, J. – Son, W. Y.**: Clinical definition paper on in vitro maturation of human oocytes. *Hum Reprod*, 2016, 31, s. 1383–1386.

16 **Chian, R. – Uzalec, P. – Nagrund, G.**: In vitro maturation of human immature oocytes for fertility preservation. *Fertil Steril*, 2013, 99, s. 1173–1181.

17 **Donnez, J. – Dolmans, M. M. – Pellicer, A., et al.**: Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation. *Fertil Steril*, 2013, 99, s. 1503–1513.

18 **Donnez, J. – Dolmans, M. M.**: Ovarian cortex transplantation: 60 reported live births brings the success and worldwide expansion of the technique towards routine clinical practice. *J Assist Reprod Genet*, 2015, 32, s. 1167–1170.

19 **Dolmans, M. M. – Luyckx, V. – Donnez, J., et al.**: Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. *Fertil Steril*, 2013, 99, s. 1514–1522.

Léčba karcinomu prsu – aktuálně a pohled do budoucna

MUDr. Marta Krásenská Klinika komplexní onkologické péče, MOÚ, Brno

1 Národní onkologický registr 2015. Karcinom prsu – incidence a mortalita. Dostupné z: www.svod.cz/analyse.php?modul=incmor#, vyhledáno 11. 4. 2018.

2 **Francis, P. A. – Regan, M. M. – Fleming, G. F., et al.**: Adjuvant ovarian suppression in premenopausal breast cancer. *N Engl J Med,* 2015, 372, s. 436–446.

3 **Pagani, O. – Regan, M. M. – Walley, B. A., et al.**: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *N Engl J Med,* 2014, 371, s. 107–118.

4 **Davies, Ch. – Pan, H. – Gray, R., et al.**: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet,* 2013, 381, s. 805–816.

5 **Gray, R. G. – Rea, D. – Handley, K., et al.**: aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. *J Clin Oncol,* 2013, 18, suppl. 5–5.

6 **Curigliano, G. – Burstein, H. J. – Winer, E. P., et al.**: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol,* 2017, 28, s. 1700–1712.

7 **Early Breast Cancer Trialists Collaborative Group (EBCTCG)**: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. *Lancet,* 2011, 378 , s. 771–784.

8 **Early Breast Cancer Trialists Collaborative Group (EBCTCG)**: Aromatase inhibitors versus tamoxifen in early breast cancer: patient--level meta-analysis of the randomised trials. *Lancet,* 2015, 386, s. 1341–1352.

9 **Tjan-Heijnen, V. C. – Van Hellemond, I. E. – Peer, P. G., et al.**: First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2–3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer. In: San Antonio Breast Cancer Symposium 2016, 6.–10. 12. 2016, San Antonio, TX, abstrakt S1–03.

10 **Blok, E. J. – van de Velde, C. J. H. – Meershoek-Klein Kranenbarg, E. M., et al.**: Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05). In: San Antonio Breast Cancer Symposium 2016, 6.–10. 12. 2016, San Antonio, TX, abstrakt S1–04.

11 **Mamounas, E. P. – Bandos, H. – Lembersky, B. C., et al.**: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjutant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42. San Antonio Breast Cancer Symposium 2016, 6.–10. 12. 2016, San Antonio, TX, abstrakt S1–05.

12 **Goss, P. E. – Ingle, J. N. – Pritchard, K. I., et al.**: Extending aromatase-inhibitor adjuvant therapy to 10 years. *N Engl J Med,* 2016, 375, s. 209–219.

13 **Metzger Filho, O. – Giobbie-Hurder, A. – Mallon, E., et al.**: Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. *J ClinOncol,* 2015, 33, s. 2772–2779.

14 **Early Breast Cancer Trialists Collaborative Group (EBCTCG)**: Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. *Lancet*, 2015, 386, s. 1353–1361; Erratum. *Lancet,* 2016, 387, s. 30.

15 **Early Breast Cancer Trialists Collaborative Group (EBCTCG)**: Comparisons between different polychemotherapy regiment for early breast cancer: meta-analysesof long-term outcome among 100,000 women in 123 randomized trials. *Lancet,* 2012, 379, s. 432–444.

16 **Sparano, J. A. – Gray, R. J. – Makower, D. F., et al.**: Prospective validation of a 21-gene expressionassay in breast cancer. *N Engl J Med,* 2015, 373, s. 2005–2014.

17 **Tolaney, S. M. – Barry, W. T. – Dang, C. T., et al.**: Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. *N Engl J Med,* 2015, 372, s. 134–141.

18 **Gianni, L. – Pienkowski, T. – Im, Y. H., et al.**: 5-Year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open label, phase 2 randomised trial. *Lancet Oncol,* 2016, 17, s. 791–800.

19 **Chan, A. – Delaloge, S. – Holmes, F. A., et al.**; ExteNET Study Group: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol,* 2016, 17, s. 367–377.

20 **Cardoso, F. – Costa, A. – Senkus, E., et al.**: 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). *Ann Oncol,* 2017, 28, s. 16–33.

21 **Baselga, J. – Cortés, J. – Kim, S. B., et al.**: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *New Engl J Med,* 2012, 366, s. 109–119.

22 **Swain, S. – Kim, S. B. – Cortes, J., et al.**: Final overal survival analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer. Prezentováno na ESMO 2014, 26.–30. 9. 2014, Madrid, Španělsko, abstrakt 3500.

23 **Kaufman, B. – Mackey, J. R. – Clemens, M. R., et al.**: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with humane dermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: result from the randomized phase III TAnDEM study. *J ClinOncol,* 2009, 27, s. 5529–5537.

24 **Krop, I. E. – Lin, N. U. – Blackwell, K., et al.**: Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. *Ann Oncol,* 2015, 26, s. 113–119.

25 **Geyer, C. E. – Forster, J. – Lindquist, D., et al.**: Lapatinib plus capecitabine for HER-2 positive advanced breast cancer. *N Engl J Med,* 2006, 355, s. 2733–2743.

26 **Tutt, A. – Ellis, P. – Kilburn, L., et al.**: TNT: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). In: San Antonio Breast Cancer Symposium 2014, 9.–13. 12. 2014, San Antonio, TX, abstrakt S3–01.

27 **Nanda, R. – Chow, L. Q. – Dees, E. C., et al.**: Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. *J Clin Oncol,* 2016, 34, s. 2460–2467.

28 **Dirix, L. Y. – Takacs, I. – Nikolinakos, P., et al.**: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial. In: San Antonio Breast Cancer Symposium 2015, 8.–12. 12. 2015, San Antonio, TX, abstrakt S1–04.

29 **Adams, S. – Diamond, J. R. – Hamilton, E. P.**: Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). *J Clin Oncol,* 2016, 34, suppl., abstrakt 1009.

30 **Robertson, J. F. R. – Bondarenko, I. M. – Trishkina, E., et al.**: Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced brest cancer (FALCON): an international, randomised, double-blind, phase 3 trial. *Lancet,* 2016, 388, s. 2997–3005.

31 **Cardoso, F. – Costa, A. – Norton, L., et al.**: ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). *Ann Oncol,* 2014, 25, s. 1871–1888.

32 **Piccart, M. – Hortobagyi, G. N. – Campone, M., et al.**: Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. *Ann Oncol,* 2014, 25, s. 2357–2362.

33 **Finn, R. S. – Martin, M. – Rugo, H. S., et al.**: Palbociclib and letrozole in advanced breast cancer. *N Engl J Med,* 2016, 375, s. 1925–1936.

34 **Hortobagyi, G. N. – Stemmer, S. M. – Burris, H. A., et al.**: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. *N Engl J Med,* 2016, 375, s. 1738–1748.

35 **Turner, N. C. – Ro, J. – Andre, F., et al.**: PALOMA3 Study Group. Palbociclib in hormone-receptor-positive advanced breast cancer. *N Engl J Med,* 2015, 373, s. 209–219.

36 **Sledge, G. W. Jr. – Toi, M. – Neven, P., et al.**: MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2– advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol,* 2017, 35, s. 2875–2884.

37 **Cortes, J. – O'Shaughnessy, J. – Loesch, D., et al.**: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. *Lancet,* 2011, 377, s. 914–923.

38 **Finn, R. S. – Crown, J. P. – Lang, I., et al.**: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. *Lancet*, 2015, 16, s. 25–35.

Mezioborová spolupráce při léčbě karcinomu močového měchýře

MUDr. Darja Šustrová Onkologická klinika FN v Motole a 2. LF UK, Praha

MUDr. Pavel Dušek, Ph.D. Urologická klinika FN v Motole a 2. LF UK, Praha

1 **Bellmunt, J. – Raghaven, D., et al.**: Treatment of metastatic urothelial cancer of the bladder and urinary tract. 2018. Dostupné z: https://www.uptodate.com, vyhledáno 11. 5. 2018.

2 Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. *Eur Urol*, 2005, 48, s. 202.

3 **Yin, M., et al.**: Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis. *Oncologist*, 2016, 21, s. 708.

4 **Grossman, H. B., et al.**: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *N Engl J Med*, 2003, 349, s. 859.

5 **Griffiths, G., et al.**: International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle--invasive bladder cancer: long-term results of the BA06 30894 trial. *J Clin Oncol*, 2011, 29, s. 2171.

6 **Grossman, H. B., et al.**: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *N Engl J Med*, 2003, 349, s. 859.

7 *Modrá kniha České onkologické společnosti*, platnost od 1. 3. 2018.

8 **Rosenblatt, R., et al.**: Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. *Eur Urol*, 2012, 61, s. 1229.

9 **Stein, J. P.**: Contemporary concepts of radical cystectomy and the treatment of bladder cancer. *J Urol*, 2003, 169, s. 116.

10 **Griffiths, G., et al.**: International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle--invasive bladder cancer: long-term results of the BA06 30894 trial. *J Clin Oncol*, 2011, 29, s. 2171.

11 **Sternberg, C. N. – Skoneczna, I. – Kerst, J. M., et al.**: Ommediate versus defferd chemotherapy after cystectomy in patient with pT3--pT4 or N+M0 urothelila carcinoma of the bladder (EORTC 30994) an intergroup, open label randomised phase 3 trial. *Lancet Oncol*, 2015, 16, s. 76–86.

12 **Orsatti, M., et al.**: Alternating chemo-radiotherapy in bladder cancer: a conservative approach. *Int J Radiat Oncol Biol Phys*, 1995, 33, s. 173.

13 **Premo, Ch. – Apolo, A. B. – Agarwal, P. K., et al.**: Trimodality therapy in bladder cancer: Who, what and when? *Urol Clin North Am*, 2015, 42, s. 169–vii.

14 **Balar, A. V. – Castellano, D. – O'Donnell, P. H., et al.**: First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study. *Lancet Oncol*, 2017, 18, s. 1483–1492.

15 **Rosenberg, J. E.**: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet*, 2016, 387, s. 1909–1920.

16 **Balar, A. V. – Galsky, M. D. – Rosenberg, J. E., et al.**: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. *Lancet*, 2017, 389, s. 67–76.

17 **Sharma, P. – Retz, M. – Siefker-Radtke, A., et al.**: Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. *Lancet Oncol*, 2017, 18, s. 312–322.

18 **Bellmunt, J. J. – de Wit, R. – Vaughn, D. J., et al.**: Pembrolizumab as second line therapy in advanced urothelial carcinoma. *NEJM*, 2017, 376, s. 1015–1026.

19 **Massard, Ch. – Gordon, M. S. – Sharma, S., et al.**: Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. *J Clin Oncol*, 2016, 34, s. 3119–3125.

20 **Patel, M. – Ellerton, J. – Infante, J. R., et al.**: Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. *Lancet Oncol*, 2017, s. 51–64.

21 **Carbone, D. P. – Reck, M. – Paz-Ares, L., et al.**; CheckMate 026 Investigators: First-line nivolumab in stage IV or recurrent non-small--cell lung cancer. *N Engl J Med*, 2017, 376, s. 2415–2426.

22 **Plataniotis, G. A. – Dale, R. G.**: Radio-chemotherapy for bladder cancer: Contribution of chemotherapy on local control. *World J Radiol*, 2013, 5, s. 267–274.

23 **Tester, W. – Porter, A. – Asbell, S., et al.**: Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. *Int J Radiat Oncol Biol Phys*, 1993, 25, s. 783–790.

24 **Tester, W. – Caplan, R. – Heaney, J., et al.**: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. *J Clin Oncol*, 1996, 14, s. 119–126.

25 **Shipley, W. U. – Winter, K. A. – Kaufman, D. S., et al.**: Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. *J Clin Oncol*, 1998, 16, s. 3576–3583.

26 **Kaufman, D. S. – Winter, K. A. – Shipley, W. U., et al.**: The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. *Oncologist*, 2000, 5, s. 471–476.

27 **Hagan, M. P. – Winter, K. A. – Kaufman, D. S.**: RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. *Int J Radiat Oncol Biol Phys*, 2003, 57, s. 665–672.

28 Maria De Santis Kaiser Franz Josef – Spital, Vienna Center for Oncology and Hematology and LBI-ACR and ACR-ITR VIEnna B L A D D E R C A N C E R Palliative chemotherapy – first line, second line, platinum unfit. Lugano, 12. 5. 2011.

Léčba neinvazivního karcinomu močového měchýře

MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení, FN u svaté Anny v Brně
MUDr. Petr Filipenský, Ph.D. Urologické oddělení, FN u svaté Anny v Brně

1 **Matoušková, M. – Svoboda, T. – Soukup, V., et al.**: Multimodální přístup k nádorům močového měchýře a prostaty. *Solen*, 2017, s. 16.
2 **Schned, A. R. – Andrew, A. S. – Marsit, C. J., et al.**: Histological classification and stage of newly diagnosed bladder cancer in a population-based study from the Northeastern United States. *Scand J Urol Nephrol*, 2008, 42, s. 237–242.
3 **Allard, P. – Bernard, P. – Fradet, Y., et al.**: The early clinical course of primary Ta and T1 bladder cancer: aproposed prognostic index. *Br J Urol*, 1998, 81, s. 692–698.
4 **Kurth, K. H. – Denis, L. – Bouffioux, C., et al.**: Factor saffecting recurrence and progression in superficial bladder tumours. *Eur J Cancer*, 1995, 31A, s. 1840–1846.
5 **Sylvester, R. J. – Oosterlinck, W. – van der Meijden, A. P.**: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage TaT1 bladder cancer: a meta-analysis of Publisher results of randomized clinical trials. *J Urol*, 2004, 171, s. 2186.
6 **Sylvester, R. J. – Oosterlinck, W. – Holmang, S., et al.**: Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? *Eur Urol*, 2016, 69, s. 231.
7 **Babjuk, M. – Burger, M. – Zigeuner R., et al.**: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. *Eur Urol*, 2013, 64, s. 639–653.
8 **Karmašová, K. – Vít, V. – Pacík, D.**: Intravezikální instilační terapie povrchového karcinomu močového měchýře. *Urol List*, 2011, 9, s. 22–26.
9 Dostupné z: www.cus.cz/pro-odborniky/aktuality/nedostupnost-bcg-vakciny-na-nasem-trhu/, vyhledáno 4. 5. 2018.

Vitamin D a nádorová prevence

MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě; 3. LF UK; IPVZ, Praha

1 **Kwan, H. Y. – Chao, X. – Su, T., et al.**: The anti cancer and anti obesity effects of Mediterranean diet. *Critical Reviews in Food Science and Nutrition*, 2017, 57, s. 82–94.
2 **Anand, P. – Kunnumakkara, A.B. – Sundaram, C., et al.**: Cancer is a preventable disease that requires major life style changes. *Pharm Res*, 2008, 25, s. 2097–2116.
3 **Bishayee, A. – Haskell, Y. – Do, C., et al.**: Potential benefits of edible berries in the management of aerodigestive and gastrointestinal tract cancers: preclinical and clinical evidence. *Critical Reviews in Food Science and Nutrition*, 2016, 56, s. 1753–1775.
4 **Pelucchi, C. – Bosetti, C. – Rossi, M., et al.**: Selected aspects of Mediterranean diet and cancer risk. *Nutrition and cancer*, 2009, 61, s. 756–766.
5 **Gandini, S. – Boniol, M. – Haukka, J., et al.**: Meta-analysis of observational studies of serum 25-hydroxy vitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. *Int J Cancer*, 2011, 128, s. 1414–1424.
6 **Ma, Y. – Zhang, P. – Wang, F., et al.**: Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. *J Clin Oncol*, 2011, 29, s. 3775–3782.
7 **Bouillon, R. – Eelen, G. – Verlinden, L., et al.**: Vitamin D and cancer. *J Steroid Biochem Mol Biol*, 2006, 102, s. 156.
8 **Matsumoto, Y. – Kittaka, A. – Chen, T. C.**: 19-Norvitamin D analogs for breast cancer therapy. *Canad J Physiol Pharm*, 2015, 93, s. 333–348.
9 **Rose, A. A. – Elser, C. – Ennis, M., et al.**: Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis. *Breast Canc Res Treat*, 2013, 141, s. 331–339.
10 **Lim, S. T. – Jeon, Y. W. – Suh, Y. J.**: Association between alterations in the serum25-hydroxy vitamin D status during follow-up and breast cancer patient prognosis. *APJCP*, 2015, 16, s. 2507–2513.
11 **Bauer, S. R. – Hankinson, S. E. – Bertone-Johnson, E. R. – Ding, E. L.**: Plasma vitamin D levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies. *Medicine*, 2013, 92, s. 123–131.
12 **Rose, A. A. – Elser, C. – Ennis, M. – Goodwin, P. J.**: Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis. *Breast Canc Res Treat*, 2013, 141, s. 331–339.
13 **Cauley, J. A. – Chlebowski, R. T. – Wactawski-Wende, J., et al.**: Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women's Health Initiative. *J Women's Health (2002)*, 2013, 22, s. 915–929.
14 **Chlebowski, R. T. – Johnson, K. C. – Kooperberg, C., et al.**: Calcium plus vitamin D supplementation and the risk of breast cancer. *J Nat Cancer Inst*, 2008, 100, s. 1581–1591.
15 IARC. Vitamin D and Cancer. IARC Working Group Reports Vol.5, International Agency for research on Cancer, Lyon. November 2008. Dostupné z: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk5/Report_VitD.pdf, vyhledáno 6. 5. 2018.
16 **Chung, M. – Lee, J. – Terasawa, T., et al.**: Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. *Ann Intern Med*, 2011, 155, s. 827.
17 **Jenab, M. – Bueno-de-Mesquita, H. B. – Ferrari, P., et al.**: Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. *BMJ*, 2010, 340, s. b5500.
18 **Maalmi, H. – Walter, V. – Jansen, L., et al.**: Dose-response relation ship between serum retinol levels and survival in patients with colorectal cancer: results from the DACHS study. *Nutrients*, 2018, 10, 4.
19 **Maalmi, H. – Walter, V. – Jansen, L., et al.**: Relation ship of very low-serum 25-hydroxyvitamin D3 levels with long-term survival in a large kohort of colorectal cancer patients from Germany. *Eur J Epidemiol*, 2017, 32, s. 961–971.
20 **Wu, D. B. – Wang, M. L. – Chen, E. Q., et al.**: New insights into the role of vitamin D in hepatocellular carcinoma. *Exp Rev Gastroenterol Hepatol*, 2018, 12, s. 287–294.
21 **Liu, Y. – Wang, X. – Sun, X., et al.**: Vitamin in take and pancreatic cancer risk reduction: A meta-analysis of observational studies. *Medicine*, 2018, 97, s. e0114.
22 **Stolzenberg-Solomon, R. Z. – Jacobs, E. J. – Arslan, A. A., et al.**: Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. *Am J Epidemiol*, 2010, 172, s. 81.
23 **Campolina-Silva, G. H. – Maria, B. T. – Mahecha, G. A. B., et al.**: Reduced vitamin D receptor (VDR) expression and plasma vitamin D levels are associated with aging-related prostate lesions. *Prostate*, 2018, 78, s. 532–546.
24 **Ahn, J. – Peters, U. – Albanes, D., et al.**: Serum vitamin D concentration and prostate cancer risk: a nested case-control study. *J Nat Cancer Inst*, 2008, 100, s. 796.
25 **Shui, I. M. – Mucci, L. A. – Kraft, P., et al.**: Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. *J Nat Cancer Inst*, 2012, 104, s. 690.
26 **Ong, J. S. – Cuellar-Partida, G. – Lu, Y., et al.**: Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. *Int J Epidemiol*, 2016, 45, s. 1619–1630.
27 **Bjelakovic, G. – Gluud, L. L. – Nikolova, D., et al.**: Vitamin D supplementation for prevention of cancer in adults. *Cochrane Database Syst Rev*, 2014, CD007469.
28 **Lappe, J. – Watson, P. – Travers-Gustafson, D., et al.**: Effect of vitamin D and calcium supplementation on cancer incidence in older women: a randomized clinical trial. *JAMA*, 2017, 317, s. 1234.

Antikoncepce: benefity, rizika, mýty

MUDr. PhDr. Pavel Čepický, CSc. Gynekologicko-porodnická ambulance LEVRET, s. r. o.

1 **Čepický, P.**: *Úvod do antikoncepce pro lékaře negynekology*. Praha, Levret, 2002 (2. upravené vydání s M. Fantou 2010). Text 1. vydání je dostupný z: http://www.antikoncepceprotebe.cz/uvod-do-antikoncepce, vyhledáno 3. 4. 2018.
2 **Čepický, P., et al.**: Doporučení k předpisu gestagenní antikoncepce. Aktualizace 2006. *Čes Gynek*, 2006, 71, s. 426–427.
3 **Čepický, P., et al.**: Doporučení k předpisu nitroděložního systému s levonorgestrelem (LNG-IUS). Aktualizace 2006. *Čes Gynek*, 2007, 72, s. 149–150.
7 **Fait, T.**: *Antikoncepce: Průvodce ošetřujícího lékaře*. Praha, Maxdorf, 2012.
8 **Křepelka, P.**: *Hormonální antikoncepce*. Praha, Mladá fronta, 2013.
9 **Unzeitig, V., et al.**: Doporučení k předpisu kombinované hormonální antikoncepce. *Čes Gynek*, 2012, 77, s. 75–77.

Farmakologická léčba hyperaktivního močového měchýře

MUDr. Alexandra Gregušová | MUDr. Zuzana Kachlířová Urologická klinika 3. LF UK a FN Královské Vinohrady, Praha

1 **Kachlířová, Z. – Horčička, L.**: Hyperaktivní močový měchýř – možnosti léčby v roce 2012. *Remedia*, 2012. Dostupné z: www.remedia.cz.
2 **Gacci, M. – Sebastianelli, A. – Spatafora, P., et al.**: Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base. *Ther Adv Urol*, 2018, 10, s. 79–92.
3 **Hegde, S. S.**: Muscarinic receptors in the bladder: from basic research to therapeutics. *Br J Pharmacol*, 2006, 147, suppl. 2, s. 80–87.
4 **Stamm, A. W. – Adelstein, S. A. – Chen, A., et al.**: Inconsistency in the definition of urinary tract infection after intravesical botulinum toxin A injection: a systematic review. *J Urol*, 2018, pii: S0022-5347(18)42924–42922.
5 **Freeman, R. – Foley, S. – Rosa Arias, J., et al.**: Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study. *Curr Med Res Opin*, 18. 12. 2017, s. 1–9.
6 **Krhut, J.**: *Hyperaktivní močový měchýř*. Praha, Maxdorf, 2007.
7 **Mašata, J.**: Anticholinergní látky v léčbě hyperaktivního močového měchýře. *Remedia*, 2007, 17, s. 89–100.

Recidivující infekce močových cest – nové řešení

MUDr. Jiří Balák, FEBU Poliklinika Hvězdova, Praha

1 **Damiano, R. – Quarto, G. – Bava, I., et al.**: Prevention of recurrent urinary tract infections by intravesical administrativ of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. *Eur Urol*, 2011, 59, s. 645–651, doi: 10.1016/j.eururo.2010.12.039, Epub 18. 1. 2011.
2 **Nightingale, G. G. – Shehab, Q. – Kandiah, C., et al.**: The effect of

intravesical instillations with hyaluronic acid on sexual dysfunction in women with recurrent urinary tractin fections (RUTI). *Taiwan J Obstet Gynecol*, 2015, 54, s. 537–540, doi: 10.1016/j.tjog.2015.03.005.
3 **Gugliotta, G. – Calagna, G. – Adile, G., et al.**: Is intravesical instillation of hyaluronic acid and chondroitin sulfate useful in preventiv recurrent bacterial cystitis? A multicenter case control analysis. *Taiwan J Obstet Gynecol*, 2015, 54, s. 537–540, doi: 10.1016/j.tjog.2015.03.005.
4 **Cervigni, M. – Sommariva, M. – Tenaglia, R., et al.**: A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethylsulfoxide in women with bladder pain syndrome/interstitial cystitis. *Neurourol Urodyn*, 2017, 36, s. 1178–1186, doi: 10.1002/nau.23091, Epub 21. 9. 2016.
5 Guidelines EAU – Urological infections (2018 update). Dostupné z: http://uroweb.org/guideline/urological-infections/#3_5s, vyhledáno 22. 5. 2018.
6 Product monography, Teva UK Ltd. Data on File. Září 2011.
7 Návod k použití Cystistat.

Poznámky k volbě gestagenu v gynekologické praxi

doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 2. LF UK a FN v Motole, Praha

1 **Varila, E. – Wahlstrom, T. – Rauramo, I.**: A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. *Fertil Steril,* 2001, 76, s. 969–973.
2 **Suvanto-Luukkonen, E. – Malinen, H., et al.**: Endometrial morfology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. *Acta Obstet Gynecol Scand,* 1998, 77, s. 758–763.
3 **Wan, Y. L. – Holland, C.**: The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review. *Climacteric,* 2011, 14, s. 622–632.
4 **Ziel, H. A. – Finkle, W. D.**: Increased risk of endometrial carcinoma among users of conjugated estrogens. *N Engl J Med,* 1975, 293, s. 1167–1170.
5 Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. Autoři neuvedeni. *JAMA*, 1996, 275, s. 370–375.
6 **Pike, M. C. – Ross, R. K.**: Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. *Steroids,* 2000, 65, s. 659–664.
7 **Gurney, E. P. – Nachtigall, M. J. – Nachtigall, L. E. – Naftolin, F.**: The WHI trial and related studies: 10 years later. *J Steroid Biochem Mol Biol*, 2014, 142, s. 4–11.
8 **Canonico, M. – Oger, E. – Plu-Bureau, G., et al.**: Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. *Circulation,* 2007, 115, s. 840–845.
9 **Fournier, A. – Berrino, F. – Clavel-Chapelon, F.**: Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. *Breast Cancer Res Treat*, 2008, 107, s. 103–111.
10 **Lyytinen, H. – Pukkala, E. – Ylikorkala, O.**: Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. *Obst Gyn,* 2009, 113, s. 65–73.
11 Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), 2013, dostupné z: www.ranzcog.edu.au, vyhledáno 2. 5. 2018.
12 **Carp, H.**: A systematic review of dydrogesterone for the treatment of threatened miscarriage. *Gynecol Endocrinol,* 2012, 28, s. 983–990.
13 **Kuhl, H.**: Pharmacology of estrogens and progestogens: influence of different routes of administration. *Climacteric*, 2006, 8, suppl. 1, s. 3–63.
14 **Schindler, A. E.**: *Maturitas*, 2003, 46, S1, s. 7–16.

Nové možnosti v léčbě vulvovaginálních infekcí

MUDr. Jiří Slíva, MD., Ph.D. Ústav farmakologie 3. LF UK, Praha

1 **Rylander, E. – Berglund, A. L. – Krassny, C., et al.**: Vulvovaginal candida in a young sexually active population: prevalence and association with oro-genital sex and frequent pain at intercourse. *Sex Transm Infect*, 2004, 80, s. 54–57.
2 **Wright, H. J. – Palmer, A.**: The prevalence and clinical diagnosis of vaginal candidosis in non-pregnant patients with vaginal discharge and pruritus vulvae. *J R Coll Gen Pract*, 1978, 28, s. 719–723.
3 **Malazy, O. T. – Shariat, M. – Heshmat, R., et al.**: Vulvovaginal candidiasis and its related factors in diabetic women. *Taiwan J Obstet Gynecol*, 2007, 46, s. 399–404.
4 **Nowakowska, D. – Kurnatowska, A. – Stray-Pedersen, B. – Wilczynski, J.**: Prevalence of fungi in the vagina, rectum and oral cavity in pregnant diabetic women: relation to gestational age and symptoms. *Acta Obstet Gynecol Scand*, 2004, 83, s. 251–256.
5 **Bailey, J. V. – Benato, R. – Owen, C. – Kavanagh, J.**: Vulvovaginal candidiasis in women who have sex with women. *Sex Transm Dis*, 2008, 35, s. 533–536.
6 **Fromtling, R. A.**: Overview of medically important antifungal azole derivatives. *Clin Microbiol Rev*, 1988, 1, s. 187–217.
7 **Palacin, C. – Tarrago, C. – Agut, J., et al.**: In vitro activity of sertaconazole, fluconazole, ketoconazole, fenticonazole, clotrimazole and itraconazole against pathogenic vaginal yeast isolates. *Methods Find Exp Clin Pharmacol*, 2001, 23, s. 61–64.
8 **Gorlero, F. – Sartani, A. – Cordaro, C. I., et al.**: Fenticonazole tissue levels after the application of 3 different dosage forms of vaginal ovules. *Int J Clin Pharmacol Ther Toxicol*, 1988, 26, s. 479–481.
9 **Novelli, A. – Periti, E. – Massi, G. B., et al.**: Systemic absorption of 3H-fenticonazole after vaginal administration of 1 gram in patients. *J Chemother*, 1991, 3, s. 23–27.
10 **Brewster, E. – Preti, P. M. – Ruffmann, R. – Studd, J.**: Effect of fenticonazole in vaginal candidiasis: a double-blind clinical trial versus clotrimazole. *J Int Med Res*, 1986, 14, s. 306–310.
11 **Wiest, W. – Ruffmann, R.**: Short-term treatment of vaginal candidiasis with fenticonazole ovules: a three-dose schedule comparative trial. *J Int Med Res*, 1987, 15, s. 319–325.
12 **Lawrence, A. G. – Houang, E. T. – Hiscock, E., et al.**: Single dose therapy of vaginal candidiasis: a comparative trial of fenticonazole vaginal ovules versus clotrimazole vaginal tablets. *Curr Med Res Opin*, 1990, 12, s. 114–120.
13 **Wiest, W. – Azzollini, E. – Ruffmann, R.**: Comparison of single administration with an ovule of 600 mg fenticonazole versus a 500 mg clotrimazole vaginal pessary in the treatment of vaginal candidiasis. *J Int Med Res*, 1989, 17, s. 369–372.
14 **Studd, J. W. – Dooley, M. M. – Welch, C. C., et al.**: Comparative clinical trial of fenticonazole ovule (600 mg) versus clotrimazole vaginal tablet (500 mg) in the treatment of symptomatic vaginal candidiasis. *Curr Med Res Opin*, 1989, 11, s. 477–484.
15 **Munoz Reyes, J. R. – Villanueva, R. C. – Ramos, C. J., et al.**: Efficacy and tolerance of 200 mg of fenticonazole versus 400 mg of miconazole in the intravaginal treatment of mycotic vulvovaginitis. *Ginecol Obstet Mex*, 2002, 70, s. 59–65.
16 **Wiest, W. – Ruffmann, R.**: Short-term treatment of vaginal candidiasis with fenticonazole ovules: a three-dose schedule comparative trial. *J Int Med Res*, 1987, 15, s. 319–325.

Význam L-methylfolátu pro organismus

RNDr. Petr Ryšávka Pharmaceutical Biotechnology, s. r. o.

1 **Nygard, O. – Nordrehaug, J. E. – Refsum, H., et al.**: Plasma omocysteine levels and mortality in patients with coronary artery disease. *N Engl J Med*, 1997, 337, s. 230–6.
2 **Hustad, S. – Midttun, O. – Schneede, J., et al.**: Hemethylene tetrahydrofolate reductase 677C-_T polymorphism as a modulator of a B vitamin network with major effects on homocysteine metabolism. *Am J Hum Genet*, 2007, 80, s. 846–855.
3 **Olthof, M. R. – Hollman, P. C. – Zock, P. L., et al.**: Consumption of high doses of chlorogenic acid, present in coffee, or of black tea increases plasma total homocysteine concentrations in humans. *Am J Clin Nutr*, 2001, 73, s. 532– 8.
4 **Strandhagen, E. – Landaas, S. – Thelle, D. S.**: Folic acid supplement decreases the homocysteine increasing effect of filtered coffee: a randomised placebo-controlled study. *Eur J Clin Nutr*, 2003, 57, s. 1411–1417.
5 **Hatzis, C. M. – Bertsias, G. K. – Linardakis, M., et al.**: Dietary and other lifestyle correlates of serum folate concentrations in a healthy adult population in Crete, Greece: a cross-sectional study. *Nutr J*, 2006, 5, s. 5.
6 **Bretthauer, M. – Gondal, G. – Larsen, K., et al.**: Design, organization and management of a controlled population screening study for detection of colorectal neoplasia: attendance rates in the NORCCAP study (Norwegian Colorectal Cancer Prevention). *Scand J astroenterol*, 2002, 37, s. 568 –73.
7 **Molloy, A. M. – Scott, J. M.**: Microbiological assay for serum, plasma, and red cell folate using cryop reserved, microtiter plate method. *Methods Enzymol*, 1997, 281, s. 43–53.
8 **Kelleher, B. P. – Broin, S. D.**: Microbiological assay for vitamin B12 performed in 96-well microtitre plates. *J Clin Pathol*, 1991, 44, s. 592–595.
9 **Midttun, O. – Hustad, S. – Solheim, E., et al.**: Multianalyte quantification of vitamin B6 and B2 species in the nanomolar range in human plasma by liquid chromatography-tandem mass spectrometry. *Clin Chem*, 2005, 51, s. 1206–1216.
10 **Fiskerstrand, T. – Refsum, H. – Kvalheim, G., et al.**: Homocysteine and other thiols in plasma and urine: automated determination and sample stability. *Clin Chem*, 1993, 39, s. 263–271.
11 **Ulvik, A. – Ueland, P. M.**: Single nucleotide polymorphism (SNP) genotyping in unprocessed whole blood and serum by real-time PCR: application to SNPsaffecting homocysteine and folate metabolism. *Clin Chem*, 2001, 47, s. 2050–2053.
12 **Koenker, R. – Hallock, K. F.**: Quantile regression. Coffee and circulating B-vitamins clinical chemistry. *J Econ Perspectives*, 2001, 15, s. 143–156.
13 **Ihaka, R. – Gentleman, R. R.**: A language for data analysis and graphics. *J Comput Graph Stat*, 1996, 5, s. 299–314.
14 R Development Core Team. A language and environment for statistical computing, 2003. Dostupné z: http://www.R-project.org, vyhledáno 23. 6. 2008.
15 **Fung, T. T. – Rimm, E. B. – Spiegelman, D., et al.**: Association between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk. *Am J Clin Nutr*, 2001, 73, s. 61–67.
16 **Esmaillzadeh, A. – Kimiagar, M. – Mehrabi, Y., et al.**: Dietary patterns, insulin resistance, and prevalence of the metabolic syndrome in women. *Am J Clin Nutr*, 2007, 85, s. 910–918.
17 **Slattery, M. L. – Boucher, K. M. – Caan, B. J., et al.**: Eating patterns and risk of colon cancer. *Am J Epidemiol*, 1998, 148, s. 4–16.
18 **Engeset, D. – Alsaker, E. – Ciampi, A., et al.**: Dietary patterns and lifestyle factors in the Norwegian EPIC cohort: the Norwegian Women and Cancer (NOWAC) study. *Eur J Clin Nutr*, 2005, 59, s. 675–684.
19 **Walmsley, C. M. – Bates, C. J. – Prentice, A., et al.**: Relation ship between cigarette smoking and nutriet intakes and blood status indices of older people living in the UK: fur the ranalysis of data from the National Diet and Nutrition Survey of people aged 65 years and over, 1994/95. *Public Health Nutr*, 1999, 2, s. 199–208.
20 **Roughead, Z. K. – McCormick, D. B.**: Urinary riboflavin and its metabolites: effects of riboflavin supplementation in healthy residents of rural Georgia (USA). *Eur J Clin Nutr*, 1991, 45, s. 299–307.
21 **Lee, C. M. – Leklem, J. E.**: Differences in vitamin B6 status indicator responses between young and middle-aged women fed constant diets with two levels of vitamin B6. *Am J Clin Nutr*, 1985, 42, s. 226–234.
22 **Suter, P. M. – Vetter, W.**: Diuretics and vitamin B1: are diuretics a risk factor for thiaminmal nutrition? *Nutr Rev*, 2000, 58, s. 319–323.
23 Shikh, E. V.: Urine levels of thiamine and riboflavine in diuretic therapy of patients with cardiovascular diseases. *Klin Med (Mosk)*, 2002, 80, s. 39–42.
24 **Mydlik, M. – Derzsiova, K. – Zemberova, E.**: Influence of water and sodium diuresis and furosemide on urinary excretion of vitamin B6, oxalic acid and vitamin C in chronic renal failure. *Miner Electrolyte Metab*, 1999, 25, s. 352–356.
25 **Mydlik, M. – Derzsiova, K. – Zemberova, E.**: Metabolism of vitamin B6 and its requirement in chronic renal failure. *Kidney Int Suppl*, 1997, 62, s. S56–59.
26 **Morrow, L. E. – Grimsley, E. W.**: Long-term diuretik therapy in hypertensive patients: effects on serum homocysteine, vitamin B6, vitamin B12, and red blood cell folate concentrations. *South Med J*, 1999, 92, s. 866–870.
27 **Shirley, D. G. – Walter, S. J. – Noormohamed, F. H.**: Natriuretic effect of caffeine: assessment of segmental sodium reabsorption in humans. *Clin Sci (Lond)*, 2002, 103, s. 461–466.

28 **Birn, H.**: The kidney in vitamin B12 and folate homeostasis: characterization of receptors for tubular uptake of vitamins and carrier proteins. *Am J Physiol Renal Physiol*, 2006, 291, s. F22–36.
29 **Kuhn, W. – Roebroek, R. – Blom, H., et al.**: Hyperhomocysteinaemia in Parkinson's disease. *J Neurol*, 1998, 245, s. 811–812.
30 **Rossi, M. – Amaretti, A. – Raimondi, S.**: Folate production by probiotic bacteria. *Nutrients*, 2011, 3, s. 118–134.
31 **Pandaac, S. H. – Dasac, S. – Balac, P., et al.**: Characterization of novel folate producing Lactobacillus rhamnosus and its appliance in fortification of ragi (Eleusine coracana) gruel. *Food Bioscience*, 2018, 21, s. 100–106.

Farmakologické umělé ukončení těhotenství na žádost ženy

MUDr. Borek Sehnal, Ph.D. | MUDr. Helena Neumannová | doc. MUDr. Michal Zikán, Ph.D.
Onkogynekologické centrum, Gynekologicko-porodnická klinika, Nemocnice Na Bulovce a 1. LF UK, Praha

1 Sbírka zákonů České republiky. Zákon České národní rady o umělém přerušení těhotenství (č. 66/1986 Sb.), vyhláška (č. 75/1986 Sb.).
2 Sbírka zákonů České republiky. Předpis č. 75/1986 Sb., vyhláška, kterou se provádí zákon č. 66/1986 Sb., o umělém přerušení těhotenství.
3 Sbírka zákonů České republiky. Předpis č. 378/2007 Sb., zákon o léčivech a o změnách některých souvisejících zákonů (zákon o léčivech).
4 **Fiala, C. – Gemzel-Danielsson, K.**: Review of medical abortion using mifepristone in combination with a prostaglandin analogue. *Contraception*, 2006, 74, s. 66–86.
5 **Fiala, C. – Cameron, S. – Bombas, T, et al.**: *Early medical abortion, a practical guide for healthcare professional*. Editions de Santé, 2012.
6 **Morris, J. L. – Winikoff, B. – Dabash, R., et al.**: FIGO's updated recommendations for misoprostol used alone in gynecology and obstetrics. *Int J Gynaecol Obstet*, 2017, 138, s. 363–366.
7 Ústav zdravotnických informací a statistiky ČR: *Potraty 2014–2015. Zdravotnická statistika*, 2016, s. 24–26.
8 AISLP. Informační systém léčivých přípravků. Dostupné z www.aislp.cz.
9 NORDIC Pharma, s. r. o., K Rybníku 475, Jesenice, Česká republika. Interní sdělení.
10 Metodický pokyn ČGPS ČLS JEP. Farmakologické ukončení těhotenství do 63. dne amenorey (gestačního stáří). *Česká Gynekol*, 2014, 78, s. 240–241.
11 **Slunská, P. – Hanáček, J. – Fanta, M., et al.**: Management umělého ukončení těhotenství farmakologickou metodou, nepřesahuje-li těhotenství 7 týdnů, v České republice. *Česká Gynekol*, 2017, 82, s. 336–344.
12 **Lubušký, M. – Procházka, M. – Šimetka, O. – Holusková, I.**: Doporučení k provádění prevence RhD aloimunizace u RhD negativních žen. Doporučený postup ČGPS ČLS JEP. *Česká Gynekol*, 2013, 78, s. 132–133.
13 Mifegyne, SPC. Dostupné z http://www.sukl.cz/modules/medication/detail.php?code=0190545&tab=texts, vyhledáno 3. 4. 2018.
14 Mispregnol, SPC. Dostupné z http://www.sukl.cz/modules/medication/detail.php?code=0183203&tab=texts, vyhledáno 3. 4. 2018.
15 **Bizjak, I. – Fiala, C. – Berggren, L., et al.**: Efficacy and safety of very early medical termination of pregnancy: a cohort study. *BJOG*, 2017, 124, s. 1993–1999.
16 Sbírka zákonů České republiky. Předpis č. 273/2015 Sb., vyhláška o stanovení hodnot bodu, výše úhrad hrazených služeb a regulačních omezení pro rok 2016.
17 Sbírka zákonů České republiky. Předpis č. 350/2015 Sb., vyhláška, kterou se mění vyhláška č. 134/1998 Sb., kterou se vydává seznam zdravotních výkonů s bodovými hodnotami, ve znění pozdějších předpisů.
18 **Frank, K. – Gerychová, R. – Janků, P., et al.**: Farmakologické ukončení gravidity mifepristonem a misoprostolem – zhodnocení úspěšnosti, komplikací a spokojenosti pacientek. *Česká Gynekol*, 2015, 80, s. 452–455.
19 **Goldstone, P. – Walker, C. – Hawtin, K.**: Efficacy and safety of mifepristone-buccal misoprostol for early medical abortion in an Australian clinical setting. *Aust N Z J Obstet Gynaecol*, 2017, 57, s. 366–371.
20 **Reeves, M. F. – Monmaney, J. A. – Creinin, M. D.**: Predictors of uterine evacuation following early medical abortion with mifepristone and misoprostol. *Contraception*, 2016, 93, s. 119–125.
21 **Šefčíková A. – Šimková, L. – Dörr, A.**: Dva roky metody medikamentózního ukončení gravidity ve Slezské nemocnici v Opavě, úspěšnost a poznatky. *Česká Gynekol*, 2017, 82, s. 206–210.
22 **Chen, M. J. – Creinin, M. D.**: Mifepristone with buccal misoprostol for medical abortion: a systematic review. *Obstet Gynecol*, 2015, 126, s. 12–21.
23 **Kapp, N. – Baldwin, M. K. – Rodriguez, M. I.**: Efficacy of medical abortion prior to 6 gestational weeks: a systematic review. *Contraception*, 2018, 97, s. 90–99.
24 **Jackson, A. V. – Dayananda, I. – Fortin, J. M., et al.**: Can women accurately assess the outcome of medical abortion based on symptoms alone? *Contraception*, 2012, 85, s. 192–197.
25 **Heller, R. – Cameron, S.**: Termination of pregnancy at very early gestation without visible yolk sac on ultrasound. *J Fam Plann Reprod Health Care*, 2015, 41, s. 90–95.
26 **Goldstone, P. – Michelson, J. – Williamson, E.**: Effectiveness of early medical abortion using low-dose mifepristone and buccal misoprostol in women with no defined intrauterine gestational sac. *Contraception*, 2013, 87, s. 855–858.
27 **Shannon, C. – Brothers, L. P. – Philip, N. M., et al.**: Ectopic pregnancy and medical abortion. *Obstet Gynecol*, 2004, 104, s. 161–167.

Transsexualita Female to Male – State in the Art v České republice

MUDr. Petra Vrzáčková, Ph.D., FECSM Gynekologicko-porodnická klinika VFN a 1. LF UK, TH klinika, s. r. o.

1 **Kuiper, B. – Cohen-Kettenis P.**: Sex reassignment: A study of 141 Dutchtranssexuals. *Arch Sex Behav*, 1998, 17, s. 439–457.
2 **Fifková, H. – Weiss, P. – Procházka, I., et al.**: *Transsexualita a jiné poruchy pohlavní identity*. Praha, Grada, 2008, 2. vydání.

Léčba pooperační bolesti po gynekologických operacích

MUDr. Marek Hakl, Ph.D. Klinika algeziologie a preventivní péče, Medicinecare, s. r. o., Chirurgická klinika FN Brno a LF MU, Brno

1 **Doležal, T. – Hakl, M. – Kozák, J., et al.**: Metodické pokyny pro farmakoterapii bolesti. *Bolest*, suppl., 2016, 1, s. 1–21.
2 **Málek, J. – Ševčík, P., et al.**: *Léčba pooperační bolesti*. Mladá fronta, 2014.
3 Oxfordská liga analgetik. Dostupné z: http://www.bandolier.org.uk/booth/painpag/Acutrev/Analgesics/Leagtab.html, vyhledáno 15. 5. 2018.
4 **Opavský, J.**: Stručný přehled farmakoterapie bolesti. *Remedia*, 1995, 5, s. 71–81.
5 **Ready, L. B. – Edwards, A.**: *Léčba akutní bolesti*. Mezinárodní společnost pro studium bolesti, Pardubice, Stapro, 1994, s. 99.